Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Tinostamustine (EDO-S101) is a new chemical entity, an AK-DAC (a first-in-class alkylating
deacetylase inhibiting molecule), that in pre-clinical studies has been shown to
simultaneously improve access to the DNA strands within cancer cells, break them and block
damage repair. This Phase 1/2 study will enroll patients with various advanced solid tumors.